A Study of DM002 in Patients With Advanced Solid Tumors

The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what

Trial Details

NCT ID
NCT06751329
Phase
PHASE1 / PHASE2
Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • DM002
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643
  • Houston, Texas, United States|29.76328,-95.36327
  • Randwick, New South Wales, Australia|-33.91439,151.24895

Key Eligibility Criteria

  • Common Inclusion Criteria (Part 1 and Part 2)
  • Subjects must have the ability to understand and willingness to sign a written informed consent document.
  • Subjects must be ≥18 years of age at the time of signing the informed consent form.
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →